CEO XOMETRY Shares Sold in 1,500‑Share 10b‑5‑1 Sale Amid Social‑Media Buzz Spike

Insider Selling Spree at XOMETRY: What the Numbers Tell Investors

On September 14, 2026, Chief Executive Officer Sahni Sanjeev Singh executed a sizable Rule 10b‑5‑1 compliant sale of 1,500 shares of XOMETRY’s Class A common stock, part of a broader series of trades that day. The shares were sold at an average price of $84.23 for the first tranche and $85.04 for the second, with the final block clearing at $86.02—well above the day’s closing price of $87.59. The transaction reduced Singh’s holdings to 180,903 shares, a drop of roughly 1 % from his pre‑sale balance. While the dollar value of the sale—about $135,000—might seem modest in the context of XOMETRY’s $4.94 billion market cap, the move is significant for an officer who has repeatedly turned to Rule 10b‑5‑1 plans to manage liquidity.

Implications for the Market

Singh’s trading pattern over the past months shows a consistent use of pre‑planned sales, typically in the $80‑$90 per‑share range as the stock approached its 52‑week high of $106.08. The latest sale, executed at $86.02, sits 10 % below the peak but 2 % above the current price, suggesting that Singh may be timing the market to capture upside while maintaining a long‑term stake. The fact that the sale coincided with a spike in social‑media buzz (378 %) and a neutral sentiment score indicates that investors are paying close attention; however, the lack of a negative sentiment signal mitigates concerns that this is a red flag.

From an equity‑valuation perspective, XOMETRY’s P/E ratio of –148.9 underscores that the company is still heavily growth‑oriented and not yet profitable. Insider sales, therefore, do not necessarily imply a lack of confidence. Rather, they often reflect cash‑flow needs, vesting schedules, or diversification strategies. The absence of a large block sale—only 1,500 shares—means that the transaction is unlikely to sway the market price materially, especially given the company’s substantial liquidity base (average daily volume exceeds 1.2 million shares).

What This Means for Investors

For long‑term shareholders, Singh’s disciplined use of a 10b‑5‑1 plan suggests a commitment to maintaining a sizeable stake while managing tax and liquidity needs. The timing of the sale—just after a 3.83 % monthly gain and amid a 77.70 % yearly rise—indicates that the company’s fundamentals remain strong. The AI‑enhanced marketplace model, combined with a robust partner ecosystem, continues to support revenue growth, even if profitability remains a distant horizon.

Short‑term traders should note that the recent spike in social‑media buzz could presage increased volatility. However, the company’s stable trading volume and lack of any pending large block sales reduce the risk of a sharp sell‑off. Investors could view the CEO’s sale as a signal of confidence in the long‑term trajectory rather than a sign of distress.

Sahni Sanjeev Singh: A Profile of Strategic Trading

Since joining XOMETRY, Singh has consistently leveraged Rule 10b‑5‑1 plans, selling between 4 % and 12 % of his holdings in periodic windows. His trading history reflects a pattern of selling when the stock approaches new highs, then re‑buying as it retraces. Notably, the July 2026 purchase of 40,506 shares at zero price—an error in the filing—suggests a potential administrative glitch rather than a strategic move. Over the past year, Singh’s average sale price has hovered around $90, comfortably above the 52‑week low of $35.86 and within the upper quartile of the trading range. This disciplined approach indicates that Singh views XOMETRY as a core long‑term investment, using sales primarily to fund liquidity needs and tax planning rather than to signal a lack of confidence.

Conclusion

Singh’s latest sale, while modest in scale, is part of a broader, well‑structured insider trading strategy that balances liquidity with a long‑term commitment to XOMETRY. For investors, the key takeaway is that the CEO’s use of Rule 10b‑5‑1 plans is a prudent tool rather than a warning. The company’s robust growth trajectory, coupled with a stable market presence, suggests that short‑term volatility driven by insider activity is likely to be absorbed without significant impact on the stock’s long‑term upside potential.